Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05607108 · ClinicalTrials.gov registry record · Phase 2
A Study of ZEN003694 in People With Squamous Cell Lung Cancer
A Phase 2 study of Squamous Cell Lung Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
- 7
- Study locations
NCT05607108: Recruiting Phase 2 study of Squamous Cell Lung Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
NCT05607108 is a Phase 2 study of Squamous Cell Lung Cancer that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 13 participants, below the 44-participant average among 4 other Squamous Cell Lung Cancer trials with a reported enrollment target (70% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05607108, a Phase 2 study of Squamous Cell Lung Cancer, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to find out whether ZEN003694 is an effective treatment for people with advanced squamous cell lung cancer with a mutation in the NSD3 gene. ZEN003694 is a type of drug called a BET inhibitor. Researchers think ZEN003694 may help here because the drug works by blocking a group of proteins called bromodomain and extra-terminal (BET) proteins, which may counteract the effect of NSD3 on tumor growth. Blocking these proteins may slow or stop the growth of the cancer.
Primary Outcome
Response to ZEN003694 will be determined using the sum unidimensional measurements of the target lesions present on the scan. Unidimensional measurement rules will adhere to RECIST 1.1 guidelines.(6) Classification of response will be categorized by RECIST 1.1 (CR, PR, SD, PD).
Conditions Studied
Interventions
- DRUG ZEN003694
Study Locations (7)
New York
- Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities ) - Commack
- Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (All Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities - Basking Ridge
- Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2022-11-01 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
What NCT05607108 shows while recruiting
NCT05607108 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 44-participant average among 4 other Squamous Cell Lung Cancer trials with a reported enrollment target (70% lower).
The record links to 1 condition, with Squamous Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which ZEN003694 is the first listed.
NCT05607108 lists 7 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT05607108 about?
NCT05607108 is a clinical study titled "A Study of ZEN003694 in People With Squamous Cell Lung Cancer". The purpose of this study is to find out whether ZEN003694 is an effective treatment for people with advanced squamous cell lung cancer with a mutation in the NSD3 gene. ZEN003694 is a type of drug called a BET inhibitor. Researchers think ZEN003694 may help here because the drug works by blocking ...
What is the current status of trial NCT05607108?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2022-11-01. Estimated completion is 2027-11.
What conditions does trial NCT05607108 study?
This clinical trial studies the following conditions: Squamous Cell Lung Cancer.
What interventions are being tested in trial NCT05607108?
The interventions under investigation include: ZEN003694 (DRUG).
Who is sponsoring clinical trial NCT05607108?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05607108 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
COMPLETED · Phase 2
-
A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
ACTIVE NOT RECRUITING · NA
-
Pilot Study to Evaluate Optical Frequency Domain Imaging for Diagnosis of Central Airway Disease
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI